Source
JACC Journals
This podcast by Dr. Ron Witteles reviews new data on transthyretin amyloid cardiomyopathy (ATTR‑CM), highlighting differences in transthyretin stabilization between acoramidis and tafamidis across wild-type and variant disease. The discussion underscores the clinical importance of TTR stabilization, emerging biomarkers such as serum transthyretin, and the expanding therapeutic landscape in cardiac amyloidosis.
News Url